Presynaptic Dopamine in Schizophrenia

CNS Neuroscience and Therapeutics

Volumn 17, Issue 2, 2011, Pages 104-109

  Miyake, Nobumi ^a   Thompson, Judy ^a   Skinbjerg, Mette ^a   Abi Dargham, Anissa ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

PET; Presynaptic dopamine; Schizophrenia; SPECT

Indexed keywords

6 FLUORODOPA F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; BETA LEVODOPA C 11; DOPAMINE; DOPAMINE TRANSPORTER; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; NEUROLEPTIC AGENT; TRACER; UNCLASSIFIED DRUG;

AUTOPSY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; HUMAN; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; DOPAMINE; HUMANS; MODELS, BIOLOGICAL; PRESYNAPTIC TERMINALS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 79952651318     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00230.x     Document Type: Review

References (69)

1. van Rossum JM. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966;160:492-494.
2. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-144.
3. Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 1975;72:4376-4380.
4. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;19:481-483.
5. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987;91:415-433.
6. Angrist B, van Kammen DP. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci 1984;7:388-390.
7. Weinberger DR. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-669.
8. Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang GJ, Ding YS, Dewey S. PET evaluation of the dopamine system of the human brain. J Nucl Med 1996;37:1242-1256.
9. 18F]fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978;75:464-467.
10. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-138.
11. Brown WD, Taylor MD, Roberts AD, et al. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 1999;53:1212-8.
12. Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm Suppl 2000;60:125-137.
13. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
14. Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: Comparative studies and clinical correlations. J Nucl Med 1994;35:955-963.
15. 18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996;119(Pt 6):2097-2103.
16. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
17. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
18. Cumming P, Gjedde A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 1998;29:37-61.
19. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of striatal aromatic L-amino acid decarboxylase: Effects of blockade or activation of dopamine receptors. Eur J Pharmacol 1993;238:157-164.
20. Cho S, Neff NH, Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 1997;323:149-157.
21. Danielsen EH, Smith D, Hermansen F, Gjedde A, Cumming P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 2001;41:172-175.
22. Torstenson R, Hartvig P, Langstrom B, Bastami S, Antoni G, Tedroff J. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 1998;37:989-995.
23. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
24. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000;20:423-451.
25. Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA. Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 2000;47:361-370.
26. Akil M, Pierri JN, Whitehead RE, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 1999;156:1580-1589.
27. 2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988;2:546-557.
28. 2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry 1994;36:827-835.
29. Hirai M, Kitamura N, Hashimoto T, et al. [3H]GBR-12935 binding sites in human striatal membranes: Binding characteristics and changes in parkinsonians and schizophrenics. Jpn J Pharmacol 1988;47:237-243.
30. Czudek C, Reynolds GP. [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. J Neural Transm 1989;77:227-230.
31. Pearce RK, Seeman P, Jellinger K, Tourtellotte WW. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur Neurol 1990;30(Suppl 1):9-14.
32. Chinaglia G, Alvarez FJ, Probst A, Palacios JM. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: A quantitative autoradiographic study using [3H]mazindol. Neuroscience 1992;49:317-327.
33. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994;91:11651-11654.
34. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995;346:1130-1131.
35. Hietala J, Syvalahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 1999;35:41-50.
36. Lindstrom LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999;46:681-688.
37. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009;66:13-20.
38. 18F]fluorodopa study. Arch Gen Psychiatry 2004;61:134-142.
39. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-271.
40. Nozaki S, Kato M, Takano H, et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 2009;108:78-84.
41. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007;51:s13-s18.
42. Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 2008;63:114-117.
43. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996;93:9235-9240.
44. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 1998;155:761-767.
45. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;94:2569-2574.
46. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 1999;46:56-72.
47. Abi-Dargham A, Kegeles L, Zea-Ponce Y, et al. Amphetamine-induced dopamine release in patients with schizotypal personality disorders studied by SPECT and [123I]IBZM. Biol Psychiatry 2004;55:1001-1006.
48. Laruelle M, DSouza CD, Baldwin RM, et al. Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997;17:162-174.
49. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000;97:8104-8109.
50. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003;23:285-300.
51. 2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21:1034-1057.
52. Kegeles L, Abi-Dargham A, Frankle W, et al. Increased synaptic dopamine in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010;67:231-239.
53. Abi-Dargham A, Giessen EV, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009;65:1091-1093.
54. Grace AA. Dopamine. In: Davis KL, Charney DS, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology-The Fifth Generation of Progress. Philadelphia Lippincott, Williams, & Wilkins, 2002;119-132.
55. Lavalaye J, Linszen DH, Booij J, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 2001;47:59-67.
56. Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC. Dopamine transporter change in drug-naive schizophrenia: An imaging study with 99mTc-TRODAT-1. Schizoph Res 2003;65:39-46.
57. 2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: A dual-isotope SPECT study. Am J Psychiatry 2004;161:1496-1498.
58. Laakso A, Vilkman H, Alakare B, et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 2000;157:269-271.
59. Schmitt GJ, Frodl T, Dresel S, et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 2006;256:115-121.
60. Schmitt GJ, la Fougere C, Dresel S, et al. Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naive schizophrenic patients. Schizophr Res 2008;101:133-141.
61. Taylor SF, Koeppe RA, Tandon R, Zubieta JK, Frey KA. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 2000;23:667-675.
62. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 1999;13:358-371.
63. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D(2) receptors by aripiprazole in schizophrenia with PET and [(18)F]Fallypride. Neuropsychopharmacology 2008;33:3111-3125.
64. Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D(2) receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 2006;32:1209-1215.
65. 2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006;49:603-615.
66. Heckers S, Rauch SL, Goff D, et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1998;1:318-323.
67. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. Probing the human hippocampus using rCBF: Contrasts in schizophrenia. Hippocampus 2001;11:543-550.
68. Meyer-Lindenberg AS, Olsen RK, Kohn PD, et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 2005;62:379-386.
69. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 2007;27:11424-11430.